Descriptive characteristics and univariable analysis for risk of HT in the MER cohort
| Variable . | Category . | No. (%) . | SHRs (95% CI) . | P value . |
|---|---|---|---|---|
| Total | 524 (100) | |||
| Age | >60 | 300 (57.3) | 1.70 (0.68-4.22) | .25 |
| >70 | 151 (28.8) | 0.72 (0.24-2.14) | .55 | |
| Sex | Male | 233 (44.5) | 1.19 (0.51-2.80) | .69 |
| Race | White | 459 (95) | (Not modeled) | |
| Ethnicity | Hispanic/Latino | 7 (1.4) | (Not modeled) | |
| ECOG performance status | ≥2 | 31 (6.0) | 1.10 (0.15-8.16) | .98 |
| Ann Arbor stage | III-IV | 264 (51.3) | 3.43 (1.26-9.38) | .016 |
| Number of extranodal sites | ≥2 | 122 (23.4) | 3.13 (1.33-7.39) | .009 |
| Mucosal sites∗ | ≥2 | 32 (10.8) | 2.72 (0.75-9.89) | .13 |
| LDH | Greater than normal | 78 (18.0) | 2.59 (0.97-6.90) | .057 |
| Hemoglobin | <12 g/dL | 133 (30.1) | 1.00 (0.38-2.81) | .99 |
| Lymphocytes | <1000 per mm3 | 99 (20.9) | 0.74 (0.22-2.55) | .64 |
| Platelets | <100 109/L | 25 (5.1) | 0.99 (0.13-7.37) | .99 |
| IPI Group | Low (0-1) | 275 (52.5) | 1.00 (reference) | |
| Low intermediate (2) | 149 (28.4) | 7.55 (2.10-27.10) | .002 | |
| High intermediate (3) | 81 (15.5) | 8.57 (2.14-34.30) | .002 | |
| High (4-5) | 19 (3.6) | 6.65 (0.69-64.21) | .10 | |
| MALT-IPI group | Low (0) | 169 (32.3) | 1.00 (reference) | |
| Intermediate (1) | 230 (43.9) | 3.03 (0.84-10.86) | .08 | |
| High (2-3) | 125 (23.9) | 4.28 (1.10-16.60) | .036 | |
| FLIPI group | Low (0-1) | 281 (53.6) | 1.00 (reference) | |
| Intermediate (2) | 149 (28.4) | 1.86 (0.67-5.14) | .23 | |
| High (3-5) | 94 (17.9) | 2.78 (0.96-8.03) | .058 | |
| Initial management | Observation | 192 (37) | - | |
| Surgery | 43 (8.2) | - | ||
| Radiation therapy | 93 (18) | - | ||
| Systemic therapy | 174 (33.5) | - | ||
| Other (including antibiotics) | 22 (4.2) | - | ||
| Systemic therapy | Yes | 174 (33.5) | 1.03 (0.42-2.56) | .94 |
| Variable . | Category . | No. (%) . | SHRs (95% CI) . | P value . |
|---|---|---|---|---|
| Total | 524 (100) | |||
| Age | >60 | 300 (57.3) | 1.70 (0.68-4.22) | .25 |
| >70 | 151 (28.8) | 0.72 (0.24-2.14) | .55 | |
| Sex | Male | 233 (44.5) | 1.19 (0.51-2.80) | .69 |
| Race | White | 459 (95) | (Not modeled) | |
| Ethnicity | Hispanic/Latino | 7 (1.4) | (Not modeled) | |
| ECOG performance status | ≥2 | 31 (6.0) | 1.10 (0.15-8.16) | .98 |
| Ann Arbor stage | III-IV | 264 (51.3) | 3.43 (1.26-9.38) | .016 |
| Number of extranodal sites | ≥2 | 122 (23.4) | 3.13 (1.33-7.39) | .009 |
| Mucosal sites∗ | ≥2 | 32 (10.8) | 2.72 (0.75-9.89) | .13 |
| LDH | Greater than normal | 78 (18.0) | 2.59 (0.97-6.90) | .057 |
| Hemoglobin | <12 g/dL | 133 (30.1) | 1.00 (0.38-2.81) | .99 |
| Lymphocytes | <1000 per mm3 | 99 (20.9) | 0.74 (0.22-2.55) | .64 |
| Platelets | <100 109/L | 25 (5.1) | 0.99 (0.13-7.37) | .99 |
| IPI Group | Low (0-1) | 275 (52.5) | 1.00 (reference) | |
| Low intermediate (2) | 149 (28.4) | 7.55 (2.10-27.10) | .002 | |
| High intermediate (3) | 81 (15.5) | 8.57 (2.14-34.30) | .002 | |
| High (4-5) | 19 (3.6) | 6.65 (0.69-64.21) | .10 | |
| MALT-IPI group | Low (0) | 169 (32.3) | 1.00 (reference) | |
| Intermediate (1) | 230 (43.9) | 3.03 (0.84-10.86) | .08 | |
| High (2-3) | 125 (23.9) | 4.28 (1.10-16.60) | .036 | |
| FLIPI group | Low (0-1) | 281 (53.6) | 1.00 (reference) | |
| Intermediate (2) | 149 (28.4) | 1.86 (0.67-5.14) | .23 | |
| High (3-5) | 94 (17.9) | 2.78 (0.96-8.03) | .058 | |
| Initial management | Observation | 192 (37) | - | |
| Surgery | 43 (8.2) | - | ||
| Radiation therapy | 93 (18) | - | ||
| Systemic therapy | 174 (33.5) | - | ||
| Other (including antibiotics) | 22 (4.2) | - | ||
| Systemic therapy | Yes | 174 (33.5) | 1.03 (0.42-2.56) | .94 |
ECOG, Eastern Cooperative Oncology Group.
As defined by Alderuccio et al.7